Dear Editor, Since 1976 Bacillus Calmette-Guerin (an attenuated form of wild type Mycobacterium bovis; BCG) has been extensively used for the treatment of superficial bladder cancer. It is a safe and well tolerated treatment with rare adverse events including allergic reactions, granoulomatous prostitidis or epididymo-orchitis, disseminated infection and BCG sepsis1. Although cystitis is not an...

Bacillus Calmette-Guerin (BCG),4 an attenuated strain of Mycobacterium bovis, was developed as a vaccine against human tuberculosis by Calmette and Guerin at the Pasteur Institute in 1908. BCG has recently regained the spotlight in completely different roles, that of an immunological adjuvant and "'antitumor" agent. Investigations with this agent in the immunotherapy of cancer have met with var...

despite the long history of the worldwide use of bacillus calmette-guerin (bcg) vaccine, a wide spectrum of adverse reactions has been observed in a small proportion of immunized infants; the most severe complication, disseminated bcgitis, is often fatal but exceedingly rare and is considered to result from host immunodeficiency. at present, ct scan, ultrasound, x-ray and bone marrow aspiration...

The Calmette--Guerin Bacillus (BCG), an attenuated live strain of Mycobacterium bovis was originally developed by Albert Leon Charles Calmette and Camile Guerin in 1925 as a vaccine for tuberculosis. At the present, BCG is widely used as a complementary therapy for superficial bladder neoplasms. This treatment is considered to be safe and well tolerated although local and distal complications m...